NICE Turns Down Keytruda-Inlyta Combination for Renal Cell Carcinoma

The National Institute for Health and Care Excellence (NICE) has recommended against Merck’s Keytruda (Pembrolizumab) in combination with Pfizer’s Inlyta (axitinib) for untreated advanced renal cell carcinoma in adults.

The institute was uncertain about the long-term benefit, despite clinical trial evidence showing that the combination is more effective than Keytruda with sunitinib.

NICE also said that the cost-effectiveness estimates of the combination are higher than what it normally considers an acceptable use of National Health Service resources.